Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.18%
#3 CoW Protocol CoW Protocol +44.40%
#4 Glidr Glidr +36.87%
#5 Humanity Humanity +26.78%
#6 Walrus Walrus +24.24%
#7 Codatta Codatta +19.91%
#8 Enso Enso +18.69%
#9 Collector Crypt Collector Crypt +14.14%
#10 The Black Bull The Black Bull +13.35%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Arix Bioscience plc Arix Bioscience plc

Arix Bioscience plc

ARIX
Rank in Stocks #36613
Arix Bioscience plc operates as a venture capital firm, focusing its... Arix Bioscience plc operates as a venture capital firm, focusing its investments across the entire lifecycle of companies, from nascent seed-stage ventures and preclinical or clinical asset development to early, mid, and late-stage growth capital rounds, encompassing both private and public equity. The firm's investment mandate is global, targeting the biotechnology sector and seeking out entities involved in groundbreaking therapeutics, cutting-edge technologies, and broader medical innovations spanning healthcare and life sciences. Employing an evergreen funding model, Arix Bioscience predominantly deploys capital directly from its own balance sheet. It generally prefers to secure a board position within its portfolio companies and strategically exits investments once the peak value has been realized. Established in 2015 and headquartered in London, United Kingdom, the company was previously known as Perceptive Bioscience Investments Limited.
Share Price
$1.93
Last synced: 2024-02-09
Market Cap
$2.50M
Change (1 day)
6.72%
Change (1 year)
0.00%
Country
GB
Trade Arix Bioscience plc (ARIX)

Category

Healthcare
P/E ratio for Arix Bioscience plc (ARIX)
P/E ratio as of 2026 TTM: 0
According to Arix Bioscience plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Arix Bioscience plc from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.